Bio-Path Holdings Inc. (BPTH)
NASDAQ (CM) NASDAQ (CM) Primary Summary
All You Need to Know About Bio-Path (BPTH) Rating Upgrade to Buy
Bio-Path (BPTH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bio-Path (BPTH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Bio-Path (BPTH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Bio-Path Holdings, Inc. (BPTH) Q3 2024 Earnings Call Transcript
Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q3 2024 Earnings Conference Call November 15, 2024 8:30 AM ET Company Participants Will O'Connor - Managing Director & Team Lead, Stern Investor Relations Peter Nielsen - CEO and CFO Anthony Price - SVP of Finance, Accounting and Administration Operator Good morning and welcome to the Bio-Path Holdings, Incorporated Third Quarter 2024 Conference Call. All participants will be in listen-only mode.
Bio-Path Holdings Inc. (BPTH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Bio-Path Holdings Inc. ever had a stock split?
Bio-Path Holdings Inc. Profile
| Biotechnology Industry | Healthcare Sector | Vikram Paul Grover CEO | NASDAQ (CM) Exchange | 09057N409 CUSIP |
| US Country | 1 Employees | - Last Dividend | 23 Feb 2024 Last Split | 4 Mar 2008 IPO Date |
Overview
Bio-Path Holdings, Inc. is distinguished as a pioneering entity within the realm of oncology, focusing on the development of drugs using RNAi nanoparticle technologies in the United States. This innovative firm has positioned itself in the clinical and preclinical stages, dedicating its efforts towards creating groundbreaking treatments for cancer. The foundation of its research and product development lies in DNAbilize, a proprietary antisense and drug delivery technology platform. This platform is characterized by the utilization of P-ethoxy, a unique modification of the deoxyribonucleic acid (DNA) backbone, designed to shield the DNA from degradation. Established in 2007 and headquartered in Bellaire, Texas, Bio-Path is spearheading efforts to bring novel cancer treatments from the laboratory to the patient.
Products and Services
Bio-Path Holdings has cultivated a robust pipeline of drug candidates leveraging its DNAbilize technology platform, which are currently at various stages of clinical development:
- Prexigebersen - As the flagship drug candidate of Bio-Path, prexigebersen is undergoing Phase II clinical trials targeted at acute myeloid leukemia (AML) and myelodysplastic syndrome, showing promise in the treatment of these hematologic malignancies.
- BP1001-A - This drug is in the early stages of clinical evaluation (Phase I trial) and is designed to combat solid tumors. Its development signifies Bio-Path's commitment to expanding its reach beyond hematologic cancers and into solid tumor indications, reflecting the versatility of the DNAbilize technology.
- Liposomal Bcl-2 (BP1002) - Currently in Phase I clinical trial, this candidate specifically targets refractory/relapsed lymphoma and chronic lymphocytic leukemia. By aiming at the Bcl-2 protein, BP1002 exemplifies the targeted approach of Bio-Path's pipeline in tackling resistant forms of cancer.
- Liposomal STAT3 (BP1003) - Targeting a key signaling molecule, this drug is in preclinical development for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. BP1003’s focus on STAT3 underscores Bio-Path's innovative approach in addressing cancers with significant unmet medical needs.
